Mediterr J Rheumatol 2019;30(3):186-9
Interstitial Lung Disease in Anti-Synthetase Syndrome
Authors Information

1Department of Rheumatology and Clinical Immunology, University of Thessaly, Larissa, Greece 
2Department of Respiratory Medicine, University General Hospital of Larissa, Faculty of Medicine, University of Thessaly, Larissa, Greece

  1. Bartoloni E, Gonzalez-Gay MA, Scirè C, Castaneda S, Gerli R, Lopez-Longo FJ, et al. Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. Autoimmun Rev 2017;16(3):253-7. [https://doi.org/10.1016/j.autrev.2017.01.008] [PMID: 28147261]
  2. Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, Albayda J, Paik JJ, Johnson C, et al. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology (Oxford) 2017;56(6):999-1007. [https://doi.org/10.1093/rheumatology/kex021] [PMID: 28339994] [PMCID: PMC5850781]
  3. Gallay L, Gayed C, Hervier B. Antisynthetase syndrome pathogenesis: knowledge and uncertainties. Curr Opin Rheumatol 2018;30:664-73. [https://doi.org/10.1097/BOR.0000000000000555] [PMID: 30239350]
  4. Witt LJ, Curran JJ, Strek ME. The Diagnosis and Treatment of Antisynthetase Syndrome. Clin Pulm Med 2016;23(5):218-26. [https://doi.org/10.1097/CPM.0000000000000171] [PMID: 27594777] [PMCID: PMC5006392]
  5. Hervier B, Devilliers H, Stanciu R, Meyer A, Uzunhan Y, Masseau A, et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 2012;12(2):210-7. [https://doi.org/10.1016/j.autrev.2012.06.006] [PMID: 22771754]
  6. Shi J, Li S, Yang H, Zhang Y, Pang Q, Lu X, Wang G. Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies. J Rheumatol 2017;44(7):1051-7. [https://doi.org/10.3899/jrheum.161480] [PMID: 28461650]
  7. Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Sem Arthritis Rheum 2012;41(6):890-9. [https://doi.org/10.1016/j.semarthrit.2011.09.008] [PMID: 22078416]
  8. Waseda Y, Johkoh T, Egashira R, Sumikawa H, Saeki K, Watanabe S, et al. Antisynthetase syndrome: Pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases. Eur J Radiol 2016;85:1421-26. [https://doi.org/10.1016/j.ejrad.2016.05.012] [PMID: 27423682]
  9. Dieval C, Deligny C, Meyer A, Cluzel P, Champtiaux N, Lefevre G, et al. Myocarditis in Patients With Antisynthetase Syndrome: Prevalence, Presentation, and Outcomes. Medicine 2015;94(26):e798. [https://doi.org/10.1097/MD.0000000000000798] [PMID: 26131832] [PMCID: PMC4504539]
  10. Doyle TJ, Dhillon N, Madan R, Cabral F, Fletcher EA, Koontz DC, et al. Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review. J Rheumatol 2018;45(6):841-50. [https://doi.org/ 10.3899/jrheum.170541] [PMID: 29606668] [PMCID: PMC5984657]